Novartis AGFRA:NOT +3.18%83 OCF Margin % is 27.18% as of Mar. 2026, which is 12% below its 10-year median of 30.98. GuruFocus rates FRA:NOT with a GF Score™ of 83/100 and a GF Value™ of €109.77 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 959 Drug Manufacturers companies, Novartis AG ranks better than 94.68% on this metric.
The historical rank and industry rank for Novartis AG's OCF Margin % or its related term are showing as below:
FRA:NOT'
s OCF Margin % Range Over the Past 10 Years
Min: 23.21 Med: 30.98 Max: 34.27
Current: 33.91
During the past 13 years, the highest OCF Margin % of Novartis AG was 34.27%. The lowest was 23.21%. And the median was 30.98%.
FRA:NOT's OCF Margin % is ranked better than 94.68% of 959
companies
in the Drug Manufacturers industry
Industry Median: 9.95
vs FRA:NOT: 33.91
Novartis AG OCF Margin % Related Terms
Novartis AG OCF Margin % Historical Data
* Premium members only.
The historical data trend for Novartis AG's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NOT vs LLY, JNJ, ABBV: OCF Margin % Comparison
For the Drug Manufacturers - General subindustry, Novartis AG's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Novartis AG's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis AG (FRA:NOT) has a OCF Margin % of 27.18% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Novartis AG and its competitors. This is 12% below median its historical median of 30.98. Over the past decade, Novartis AG's OCF Margin % has ranged from 23.21 to 34.27. According to the industry distribution chart, Novartis AG ranks #51 out of 959 companies in the Drug Manufacturers industry, placing it in the top 5.3%.
Is Novartis AG's OCF Margin % too high?
Novartis AG's current OCF Margin % of 27.18% is 12% below median its 10-year median of 30.98. Over the past 10 years, this metric has ranged from a low of 23.21 to a high of 34.27. The Drug Manufacturers industry median OCF Margin % is 9.95. Novartis AG's value of 27.18% is 173.2% above this industry median. Based on the distribution chart, Novartis AG ranks #51 out of 959 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's OCF Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #51 out of 959 companies for OCF Margin %. This places Novartis AG in the top 5% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 9.95. Novartis AG's value of 27.18% is 173.2% above this benchmark. Historically, Novartis AG's own OCF Margin % has ranged from 23.21 to 34.27 over the past decade. While the company's 10-year median is 30.98 vs. the industry median of 9.95, Novartis AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.95, based on 959 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novartis AG's current OCF Margin % of 27.18% is 173.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Novartis AG and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis AG's current OCF Margin % is 27.18%, which is 12% below median its own 10-year median of 30.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT) is currently considered Modestly Overvalued. The stock's GF Value™ is €109.77, compared to a current price of €135.70 — trading 23.6% above its estimated fair value. The current OCF Margin % is 27.18%, which is 12% below median its 10-year median of 30.98 and 173.2% above the Drug Manufacturers industry median of 9.95. Novartis AG's overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Novartis AG (FRA:NOT), the current OCF Margin % is 27.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis AG (FRA:NOT) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued.
The current stock price of €135.70 is trading 23.6% above its estimated GF Value™ of €109.77.
GuruFocus considers Novartis AG to be Modestly Overvalued.
Key valuation signals for FRA:NOT:
OCF Margin %: 27.18% (12% below median its 10-year median of 30.98)
GF Value™: €109.77 vs. price of €135.70 (23.6% above fair value)
Industry Position: 173.2% above the Drug Manufacturers median (#51 of 959)
No single metric tells the full story. See the FRA:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score
Get the complete analysis for FRA:NOT
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NOT has been successfully added to your 
